Market Overview

Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

Share:

NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation (NYSE:BRC), Akari Therapeutics PLC (NASDAQ:AKTX), MTGE Investment Corp. (NASDAQ:MTGE), Jones Lang LaSalle Incorporated (NYSE:JLL), New Relic, Inc. (NYSE:NEWR), and Sorrento Therapeutics, Inc. (NASDAQ:SRNE), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

BRC DOWNLOAD: http://Fundamental-Markets.com/register/?so=BRC
AKTX DOWNLOAD: http://Fundamental-Markets.com/register/?so=AKTX
MTGE DOWNLOAD: http://Fundamental-Markets.com/register/?so=MTGE
JLL DOWNLOAD: http://Fundamental-Markets.com/register/?so=JLL
NEWR DOWNLOAD: http://Fundamental-Markets.com/register/?so=NEWR
SRNE DOWNLOAD: http://Fundamental-Markets.com/register/?so=SRNE

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Brady Corporation (NYSE:BRC), Akari Therapeutics PLC (NASDAQ:AKTX), MTGE Investment Corp. (NASDAQ:MTGE), Jones Lang LaSalle Incorporated (NYSE:JLL), New Relic, Inc. (NYSE:NEWR), and Sorrento Therapeutics, Inc. (NASDAQ:SRNE) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed August 30th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

BRADY CORPORATION (BRC) REPORT OVERVIEW

Brady's Recent Financial Performance

For the three months ended April 30th, 2018 vs April 30th, 2017, Brady reported revenue of $298.42MM vs $275.93MM (up 8.15%) and basic earnings per share $0.50 vs $0.44 (up 13.64%). For the twelve months ended July 31st, 2017 vs July 31st, 2016, Brady reported revenue of $1,113.32MM vs $1,120.63MM (down 0.65%) and basic earnings per share $1.86 vs $1.57 (up 18.47%). Brady is expected to report earnings on September 13th, 2018. The report will be for the fiscal period ending July 31st, 2018. The reported EPS for the same quarter last year was $0.48. The estimated EPS forecast for the next fiscal year is $2.16 and is expected to report on September 13th, 2018.

To read the full Brady Corporation (BRC) report, download it here: http://Fundamental-Markets.com/register/?so=BRC

-----------------------------------------

AKARI THERAPEUTICS PLC (AKTX) REPORT OVERVIEW

Akari Therapeutics' Recent Financial Performance

Akari Therapeutics is expected to report earnings on November 12th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.09. The estimated EPS forecast for the next fiscal year is -$1.00 and is expected to report on March 20th, 2019.

To read the full Akari Therapeutics PLC (AKTX) report, download it here: http://Fundamental-Markets.com/register/?so=AKTX

-----------------------------------------

MTGE INVESTMENT CORP. (MTGE) REPORT OVERVIEW

MTGE Investment's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, MTGE Investment reported revenue of $38.62MM vs $35.73MM (up 8.08%) and basic earnings per share $0.15 vs $0.91 (down 83.52%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, MTGE Investment reported revenue of $143.65MM vs $147.77MM (down 2.79%) and basic earnings per share $3.42 vs $0.85 (up 302.35%). MTGE Investment is expected to report earnings on September 5th, 2018. The report will be for the fiscal period ending June 30th, 2018.

To read the full MTGE Investment Corp. (MTGE) report, download it here: http://Fundamental-Markets.com/register/?so=MTGE

-----------------------------------------

JONES LANG LASALLE INCORPORATED (JLL) REPORT OVERVIEW

Jones Lang LaSalle's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Jones Lang LaSalle reported revenue of $3,903.70MM vs $3,470.30MM (up 12.49%) and basic earnings per share $2.37 vs $2.08 (up 13.94%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Jones Lang LaSalle reported revenue of $7,932.40MM vs $6,803.80MM (up 16.59%) and basic earnings per share $5.60 vs $7.04 (down 20.45%). Jones Lang LaSalle is expected to report earnings on November 5th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $1.96. The estimated EPS forecast for the next fiscal year is $10.91 and is expected to report on February 6th, 2019.

To read the full Jones Lang LaSalle Incorporated (JLL) report, download it here: http://Fundamental-Markets.com/register/?so=JLL

-----------------------------------------

NEW RELIC, INC. (NEWR) REPORT OVERVIEW

New Relic's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, New Relic reported revenue of $108.22MM vs $80.10MM (up 35.11%) and basic earnings per share -$0.10 vs -$0.30. For the twelve months ended March 31st, 2018 vs March 31st, 2017, New Relic reported revenue of $355.06MM vs $263.48MM (up 34.76%) and basic earnings per share -$0.83 vs -$1.18. New Relic is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.25. The estimated EPS forecast for the next fiscal year is -$0.19 and is expected to report on May 14th, 2019.

To read the full New Relic, Inc. (NEWR) report, download it here: http://Fundamental-Markets.com/register/?so=NEWR

-----------------------------------------

SORRENTO THERAPEUTICS, INC. (SRNE) REPORT OVERVIEW

Sorrento Therapeutics' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Sorrento Therapeutics reported revenue of $3.91MM vs $4.67MM (down 16.12%) and basic earnings per share -$0.73 vs -$0.20. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Sorrento Therapeutics reported revenue of $151.86MM vs $8.15MM (up 1,762.81%) and basic earnings per share $0.13 vs -$1.21. Sorrento Therapeutics is expected to report earnings on September 5th, 2018. The report will be for the fiscal period ending June 30th, 2018.

To read the full Sorrento Therapeutics, Inc. (SRNE) report, download it here: http://Fundamental-Markets.com/register/?so=SRNE

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

View Comments and Join the Discussion!